/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
+0.20%
Natural Gas
-1.35%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
-1.32%
VIX
N/A
Economic Calendar
EUR/USD
+0.20%
Natural Gas
-1.35%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
-1.32%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
October Retail Sales Rise 0.4%, Show Resilience Despite Slowing Momentum
3 days ago
China Retail Sales Jumps in October as Unemployment Drops to 5.0%
3 days ago
France’s Economic Strengths Balance Increasingly Challenging Fiscal, Political Outlooks
4 days ago
Crude Inventories Rise By 2.1 Million Barrels, Exceeding Analyst Estimates
4 days ago
October PPI Rises 0.2%, Supporting Fed Rate Cut Hopes as Inflation and Jobs Steady
4 days ago
Disney’s Streaming Fuels Optimism; PPI Data May Forecast Fed’s Next Steps
4 days ago
EUR/USD, USD/JPY and AUD/USD Forecast – US Dollar is Mixed Early on Monday
7 minutes ago
Natural Gas News: Colder Weather and Russia Tensions Propel Futures Towards $3.044
15 minutes ago
Earnings in Focus: How Lowe’s, Target, and Nvidia Navigated Q3 Challenges
about 2 hours ago
Silver (XAG) Forecast: Will Dollar Weakness Spark a Rebound?
about 1 hour ago
Gold News: Resistance at $2604 Holds the Key to the Next Price Breakout
about 2 hours ago
Oil News: Tensions in Ukraine Drive Crude Oil Higher Amid Bearish Market Sentiment
about 3 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
NVS
profile
Novartis AG - ADR
Follow
NVS
(
NYSE
)
Closed
103.07
-0.33 (-0.32%)
in
:
usd
•
As of: Nov 15, 2024 15:59
UTC -5
Pre Market
:
102.32
-0.75 (-0.73%)
Open
102.90
High
103.30
Low
102.58
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
Dividends
About
Novartis AG - ADR
CEO
Vasant Narasimhan
Headquarters
lichtstrasse 35
basel, v8 ch 4056, switzerland
Auditor
KPMG AG
Employees
76,057
Share Holders
N/A
Website
www.novartis.com
Industry
pharmaceuticals major
Sector
health technology
Company Overview
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Novartis AG - ADR
Statistics
Valuation Measures
Market Capitalization
2
210.68B
Enterprise Value
227.38B
Enterprise Value/EBITDA
(ttm)
13.73
Price to Earnings Ratio
(ttm)
14.00
Price to Book
(mrq)
4.85
Price to Sales
(ttm)
4.30
Price to Cash
(ytd)
9.27
Profitability
Gross Margin
(ttm)
74.90%
Operating Margin
(ttm)
30.55%
Profit Margin
(ttm)
35.90%
Return on Equity
(ttm)
34.80%
Return on Invested Capital
(ttm)
18.78%
Return on Assets
(ttm)
15.13%
Income Statement
Revenue
(ttm)
49.94B
Revenue Per Share
(ttm)
N/A
Gross Profit
(ttm)
37.41B
EBITDA
(ttm)
3
16.56B
Net Income Avi to Common
(ttm)
17.60B
Diluted EPS
(ttm)
8.61
Share Statistics
Beta (5Y Monthly)
0.58
52-Week Change
12.30%
S&P500 52-Week Change
29.10%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
N/A
Dividend Yield
2.36%
Float
4
2.04B
%
Held by Insiders
0.01%
%
Held by Institutions
13.12%
Balance Sheet
Total Cash
(mrq)
14.02B
Total Cash Per Share
(mrq)
N/A
Total Debt
(mrq)
30.32B
Total Debt/Equity
(mrq)
69.79%
Current Ratio
(mrq)
1.11%
Quick Ratio
(mrq)
0.90%
Book Value Per Share
(mrq)
21.73
Cash Flow
Operating Cash Flow Per Share
(ytd)
6.62
Free Cash Flow
(ytd)
12.66B
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker